Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
FBIOP | US
-0.07
-1.07%
Healthcare
Biotechnology
30/06/2024
30/08/2024
6.58
6.71
6.71
6.50
Fortress Biotech Inc. a biopharmaceutical company develops and commercializes pharmaceutical and biotechnology products. The company markets dermatology products such as Ximino an oral minocycline drug for the treatment of moderate to severe acne; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Exelderm cream for antifungal intended for topical use; Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Amzeeq; Zilxi; and Accutane capsules for severe recalcitrant nodular acne. It also develops late stage product candidates such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101 an injection for the treatment of Menkes disease; MB-107 and MB-207 for the treatment of X-linked severe combined immunodeficiency; Cosibelimab for metastatic cancers; CK-101 for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and CEVA101 for the treatment of severe traumatic brain injury in adults and children. The company's early stage product candidates include MB-102 for blastic plasmacytoid dendritic cell neoplasm; MB-101 for glioblastoma; MB-104 for multiple myeloma and light chain amyloidosis; MB-106 for B-cell non-hodgkin lymphoma; MB-103 for GBM & metastatic breast cancer to brain; MB-108; MB-105 for prostate and pancreatic cancers; and BAER-101. Its preclinical product candidates comprise AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302 an anti-GITR; CK-303 an anti-CAIX; and ONCOlogues and oligonucleotide platform. It has collaboration arrangements with universities research institutes and pharmaceutical companies. The company was formerly known as Coronado Biosciences Inc. and changed its name to Fortress Biotech Inc. in April 2015. Fortress Biotech Inc. was incorporated in 2006 and is based in Bay Harbor Islands Florida.
View LessNegative Momentum (Declining Price)
High 6-Month Volatility (>65%)
Microcap (<300M USD)
Risky Dividend Yield (> 12%). Dividend cuts imminent.
High Market Beta (> 0.8)
High Debt to Equity (> 0.75)
High Debt to Asset (> 0.45)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
26.7%1 month
39.1%3 months
118.5%6 months
91.2%-
-
-
4.95
0.61
-
-
-
-90.31M
35.32M
35.32M
35.62
-168.76
-
-14.30
-1.74K
0.21
-
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
0.82
Range1M
2.77
Range3M
11.27
Rel. volume
0.20
Price X volume
33.36K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
vTv Therapeutics Inc | VTVT | Biotechnology | 15.71 | 38.22M | -0.82% | n/a | 1.55% |
Equillium Inc | EQ | Biotechnology | 1.07 | 37.90M | -0.93% | n/a | 2.71% |
Xilio Therapeutics Inc. Common Stock | XLO | Biotechnology | 0.8579 | 37.71M | 6.76% | n/a | 25.98% |
Atara Biotherapeutics Inc | ATRA | Biotechnology | 7.6 | 37.35M | 7.65% | n/a | -81.03% |
Reviva Pharmaceuticals Holdings Inc. | RVPH | Biotechnology | 1.12 | 37.06M | 5.66% | n/a | 0.00% |
FibroGen Inc | FGEN | Biotechnology | 0.3656 | 36.71M | -1.48% | n/a | -70.49% |
Acurx Pharmaceuticals Inc. Common Stock | ACXP | Biotechnology | 2.2 | 35.74M | -0.45% | n/a | 0.00% |
Rafael Holdings Inc | RFL | Biotechnology | 1.45 | 35.62M | -3.33% | n/a | 2.77% |
Eyenovia Inc | EYEN | Biotechnology | 0.5501 | 35.24M | 2.78% | n/a | -662.22% |
Cue Biopharma Inc | CUE | Biotechnology | 0.7225 | 35.14M | 0.21% | n/a | 52.09% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 2.34 | 28.51M | 13.04% | n/a | 16.03% |
ILAG | ILAG | Building Products & Equipment | 1.25 | 22.57M | 6.84% | n/a | 5.48% |
Beasley Broadcast Group Inc | BBGI | Broadcasting - Radio | 0.6131 | 18.67M | -4.20% | n/a | 204.46% |
Forza X1 Inc | FRZA | Recreational Vehicles | 0.2495 | 3.93M | 5.94% | n/a | 0.00% |
Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.391 | 3.72M | -6.28% | n/a | 19.98% |
EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.45 | 3.70M | 13.28% | n/a | 9.62% |
Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 2.47 | 2.11M | -7.84% | n/a | 0.00% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | - | 0.97 | - |
Ent. to Revenue | - | 3,681.29 | - |
PE Ratio | - | 39.83 | - |
Price to Book | - | 14.54 | - |
Dividend Yield | 35.62 | 2.19 | Leader |
Std. Deviation (3M) | 118.46 | 76.13 | Riskier |
Debt to Equity | 4.95 | -2.05 | Expensive |
Debt to Assets | 0.61 | 0.25 | Expensive |
Market Cap | 35.32M | 4.04B | Emerging |